Capital Analysts LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Capital Analysts LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,512 shares of the medical research company’s stock after selling 162 shares during the period. Capital Analysts LLC’s holdings in Thermo Fisher Scientific were worth $2,395,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Savant Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock worth $1,997,000 after purchasing an additional 18 shares during the period. Sugarloaf Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock valued at $156,000 after acquiring an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton grew its holdings in shares of Thermo Fisher Scientific by 3.7% during the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after purchasing an additional 19 shares in the last quarter. Tsfg LLC raised its position in Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 19 shares during the last quarter. Finally, 1776 Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 2.4% during the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after purchasing an additional 19 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of a number of research analyst reports. Evercore ISI boosted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Finally, Raymond James upped their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $601.56.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $4.43 during trading hours on Tuesday, reaching $553.44. The company’s stock had a trading volume of 157,842 shares, compared to its average volume of 1,526,403. The company’s 50 day simple moving average is $571.79 and its 200 day simple moving average is $526.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The stock has a market cap of $211.25 billion, a P/E ratio of 36.11, a price-to-earnings-growth ratio of 2.38 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating the consensus estimate of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $5.40 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last quarter. Insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.